Literature DB >> 16437597

Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus.

Chung-Ping Hsu1, Li-Wen Lee, Sen-Ei Shai, Chih-Yi Chen.   

Abstract

AIM: To observe the interaction between the expression of telomerase activity (TA) and its associate genes in regulation of the terminal restriction fragment length (TRFL) in esophageal squamous cell carcinoma (SCC).
METHODS: Seventy-four specimens of esophageal SCC were examined. The TA was measured by telomeric repeat amplification protocol (TRAP) assay, and the associated genes [human telomerase-specific reverse transcriptase (hTERT), hTERC, TP1, c-Myc, TRF1, and TRF2] were detected using RT-PCR method. The TRFL was measured by Telomere Length Assay Kit and Southern blotting. The correlations between the expression of telomerase and its associated genes with the TRFL and survivals were examined.
RESULTS: Expressions of the TA, hTERT, hTERC, TP1, c-Myc, TRF1, and TRF2 genes were observed in 85.1%, 64.9%, 79.7%, 100.0%, 94.6%, 82.4%, and 91.9% of the tumor tissues, respectively. The TRFL of the tumor and normal esophageal tissues were 2.70+/-1.42 and 4.93+/-1.74 kb, respectively (P<0.0001). The TRFL of the telomerase positive and telomerase negative tumor tissues were 2.72+/-1.44 and 2.58+/-1.32 kb, respectively (P = 0.767). The TRFL ratios (TRFLR) of the telomerase positive and telomerase negative tumor tissues were 0.55+/-0.22 and 0.59+/-0.41, respectively (P = 0.742). The expression rates of h-TERT (P = 0.0002), hTERC (P<0.0001), and TRF1 (P = 0.002) in the tumor tissues are higher than those of the normal paired tissues. Though TA is markedly activated in tumor tissues (P<0.0001), its expression is not related to clinicopathological parameters including gender, tumor differentiation, and TNM stages. The cumulative 4-year survival rates of telomerase positive and telomerase negative cases were 35.86% and 31.2%, respectively (P = 0.8442). The cumulative 4-year survival rates of patients with their TRFLR <or=85% and >85% were 38.7% and 15.7%, respectively (P = 0.1307).
CONCLUSION: Though telomerase expression is not related to tumor stages and prognosis, our data support that the TA increased as the TRFL decreased, probably under the control of hTERT, hTERC, and TRF1. When telomerase expression was activated, only TRF2 overexpression persisted to stabilize T-loop formation. Furthermore, as the TRFLR decreased to 85%, a trend of better prognosis was observed. Cox model analysis indicates a higher t/n TRFLR and distant metastasis are independent poorer prognostic factors (P = 0.035 and P = 0.042, respectively).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437597      PMCID: PMC4717035          DOI: 10.3748/wjg.v11.i44.6941

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  Cellular senescence as a tumor-protection mechanism: the essential role of counting.

Authors:  W E Wright; J W Shay
Journal:  Curr Opin Genet Dev       Date:  2001-02       Impact factor: 5.578

2.  Control of telomere length by the human telomeric protein TRF1.

Authors:  B van Steensel; T de Lange
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

3.  Telomerase regulation during entry into the cell cycle in normal human T cells.

Authors:  K J Buchkovich; C W Greider
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

4.  Cloning of human telomeres by complementation in yeast.

Authors:  S H Cross; R C Allshire; S J McKay; N I McGill; H J Cooke
Journal:  Nature       Date:  1989-04-27       Impact factor: 49.962

5.  Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.

Authors:  D E Ayer; L Kretzner; R N Eisenman
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

6.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

7.  Tankyrase, a poly(ADP-ribose) polymerase at human telomeres.

Authors:  S Smith; I Giriat; A Schmitt; T de Lange
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

8.  Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes.

Authors:  H Vaziri; F Schächter; I Uchida; L Wei; X Zhu; R Effros; D Cohen; C B Harley
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

9.  Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas.

Authors:  Tzu-Chin Wu; Pinpin Lin; Chung-Ping Hsu; Yi-Jie Huang; Chih-Yi Chen; Wen-Chuan Chung; Huei Lee; Jiunn-Liang Ko
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

10.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.

Authors:  C M Counter; A A Avilion; C E LeFeuvre; N G Stewart; C W Greider; C B Harley; S Bacchetti
Journal:  EMBO J       Date:  1992-05       Impact factor: 11.598

View more
  11 in total

1.  Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro.

Authors:  Yun-Feng Wang; Ke-Jian Guo; Bei-Ting Huang; Yong Liu; Xiao-Yun Tang; Jian-Jun Zhang; Qiang Xia
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  Expression of Telomere Binding Proteins (RAP1 and POT1) in Renal Cell Carcinoma and Their Correlation with Clinicopathological Parameters.

Authors:  Deeksha Pal; Shrawan Kumar Singh; Nandita Kakkar; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2016-09-03

3.  The role of oncogenes in gastrointestinal cancer.

Authors:  Emmanouil P Pappou; Nita Ahuja
Journal:  Gastrointest Cancer Res       Date:  2010-11

Review 4.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

Review 5.  Telomeres and telomere dynamics: relevance to cancers of the GI tract.

Authors:  Nivedita Basu; Halcyon G Skinner; Kristin Litzelman; Russell Vanderboom; Esha Baichoo; Lisa A Boardman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-11       Impact factor: 3.869

6.  Genetic dissection of the mechanisms underlying telomere-associated diseases: impact of the TRF2 telomeric protein on mouse epidermal stem cells.

Authors:  Gerdine J Stout; Maria A Blasco
Journal:  Dis Model Mech       Date:  2009-02-23       Impact factor: 5.758

Review 7.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

8.  Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients.

Authors:  Sevgi Ozden; Pinar Mega Tiber; Zerrin Ozgen; Hazan Ozyurt; Nedime Serakinci; Oya Orun
Journal:  Biol Res       Date:  2014-11-25       Impact factor: 5.612

9.  3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.

Authors:  Erica R Heitmann; Kamani M Lankachandra; Jeff Wall; George D Harris; Hollie J McKinney; G Reza Jalali; Yogita Verma; Eric Kershnar; Michael W Kilpatrick; Petros Tsipouras; Diane M Harper
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer.

Authors:  Ana Carneiro; Anna Isinger; Anna Karlsson; Jan Johansson; Göran Jönsson; Pär-Ola Bendahl; Dan Falkenback; Britta Halvarsson; Mef Nilbert
Journal:  BMC Cancer       Date:  2008-04-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.